

Sponsor/  
Manufacturer      Digital Healthcare Inc  
Address:      343 South White Street  
                    Wake Forest  
                    NC 27587  
Phone:      919 554 9650  
Fax      919 435 5277  
e-mail      [usinfo@digital-healthcare.com](mailto:usinfo@digital-healthcare.com)

AUG 31 2007

Contact      Mr Gerry Skews  
                    Digital Healthcare Inc  
Address      343 South White Street  
                    Wake Forest  
                    NC 27587  
Phone:      919 554 9650  
Fax      919 435 5277  
e-mail      [usinfo@digital-healthcare.com](mailto:usinfo@digital-healthcare.com)

Date Prepared      April 30<sup>th</sup>, 2007

Proposed Class      II

Proprietary Name      **iP**<sup>®</sup> Digital Image and Informatics Platform to include  
                                    OcuLab **iP**<sup>®</sup> OptoMize **iP**<sup>®</sup> Retasure **iP**<sup>®</sup>

Common Name      Clinical Imaging and Data Management Software

Classification Name      HKI, NFF, NFG, **NFS**



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Digital Healthcare, Inc.  
c/o Gerry Skews  
343 South White Street  
Wake Forest, NC 27587

AUG 31 2007

Re: K071299

Trade/Device Name: iP System

Regulation Number: 21 CFR 892.2050

Regulation Name: Ophthalmic Image Management System

Regulatory Class: Class II

Product Code: NFJ, NFF, NFG, HKI

Dated: July 12, 2007

Received: July 16, 2007

Dear Mr. Skews:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic and Ear, Nose  
and Throat Devices

Office of Device Evaluation

Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known):

Device Name: iP® Digital Imaging and Informatics Management System

Indications for use: The iP® system is used by health professionals to capture, store, encode, encrypt, transmit, decrypt, decode, display, process, spatially calibrate, assess, grade and report on images and data that are captured on a range of approved medical devices that include but are not limited to :

- A. Mydriatic Fundus Cameras
- B. Non Mydriatic Fundus Cameras
- C. Scanning Laser Ophthalmoscopes
- D. Optical Coherence Tomography Instruments
- E. Bio Microscopes (Slit Lamps)
- F. Non Radiometric Ultrasound devices
- G. Video image sources
- H. TWAIN compliant imaging sources
- I. Compliant data sources placed in network accessible folders and directories
- J. Images of known format from digital cameras and scanners
- K. Electronic information complying to accepted DICOM formats
- L. Other devices connected in proprietary formats

Prescription Use  X  OR Over the counter use \_\_\_\_\_  
(21CFR 801.109 Subpart D) (21 CFR 801 subpart C)

(Please do not write below this line - Continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)  
 Division of Ophthalmic Ear,  
 Nose and Throat Devices

510(k) Number  K071299

